PL2488554T3 - Przeciwciała przeciw epha3 - Google Patents
Przeciwciała przeciw epha3Info
- Publication number
- PL2488554T3 PL2488554T3 PL10777137T PL10777137T PL2488554T3 PL 2488554 T3 PL2488554 T3 PL 2488554T3 PL 10777137 T PL10777137 T PL 10777137T PL 10777137 T PL10777137 T PL 10777137T PL 2488554 T3 PL2488554 T3 PL 2488554T3
- Authority
- PL
- Poland
- Prior art keywords
- epha3
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25166809P | 2009-10-14 | 2009-10-14 | |
| PCT/US2010/052725 WO2011053465A1 (en) | 2009-10-14 | 2010-10-14 | Antibodies to epha3 |
| EP10777137.0A EP2488554B1 (en) | 2009-10-14 | 2010-10-14 | Antibodies to epha3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2488554T3 true PL2488554T3 (pl) | 2020-03-31 |
Family
ID=43499991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10777137T PL2488554T3 (pl) | 2009-10-14 | 2010-10-14 | Przeciwciała przeciw epha3 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8664365B2 (enExample) |
| EP (1) | EP2488554B1 (enExample) |
| JP (2) | JP2013508292A (enExample) |
| CN (1) | CN102666589B (enExample) |
| AU (1) | AU2010313621C1 (enExample) |
| CA (1) | CA2777068C (enExample) |
| DK (1) | DK2488554T3 (enExample) |
| ES (1) | ES2743558T3 (enExample) |
| PL (1) | PL2488554T3 (enExample) |
| PT (1) | PT2488554T (enExample) |
| WO (1) | WO2011053465A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011235867B2 (en) * | 2010-04-01 | 2015-12-03 | Kalobios Pharmaceuticals, Inc. | EphA3 antibodies for the treatment of multiple myeloma |
| JP2013537403A (ja) * | 2010-06-18 | 2013-10-03 | カロバイオス ファーマシューティカルズ インコーポレイティッド | 固形腫瘍の存在のマーカーとしてのＥｐｈＡ３の検出 |
| US9109032B2 (en) | 2011-08-12 | 2015-08-18 | Kalobios Pharmaceuticals, Inc. | Methods of treating hematological proliferative disorders by targeting EphA3 expressed on aberrant vasculature in bone marrow |
| PL3708583T3 (pl) | 2013-08-01 | 2022-06-06 | Five Prime Therapeutics, Inc. | Afukozylowane przeciwciała anty-fgfr2iiib |
| JP7349787B2 (ja) | 2015-11-23 | 2023-09-25 | ファイヴ プライム セラピューティクス インク | 癌治療におけるｆｇｆｒ２阻害剤単独または免疫刺激剤との組み合わせ |
| US20190270821A1 (en) * | 2016-09-13 | 2019-09-05 | Humanigen, Inc. | Epha3 antibodies for the treatment of pulmonary fibrosis |
| JP7299842B2 (ja) | 2017-05-16 | 2023-06-28 | ファイヴ プライム セラピューティクス インク | がん治療における化学療法剤と組み合わせた抗ｆｇｆｒ２抗体 |
| WO2019165982A1 (en) * | 2018-02-28 | 2019-09-06 | WuXi Biologics Ireland Limited | Monoclonal antibody against human lag-3, method for preparing same, and use thereof |
| WO2021068040A1 (en) * | 2019-10-09 | 2021-04-15 | The Council Of The Queensland Institute Of Medical Research | Targeting epha3 and uses thereof |
| TW202134278A (zh) | 2019-11-08 | 2021-09-16 | 美商胡曼尼根公司 | 用於治療腫瘤之ｅｐｈａ３導向ｃａｒ－ｔ細胞 |
| US20240025971A1 (en) * | 2020-10-23 | 2024-01-25 | Atreca, Inc. | Antibodies to coronavirus sars-cov-2 |
| JP7726496B2 (ja) * | 2021-08-06 | 2025-08-20 | コリア リサーチ インスティチュート オブ バイオサイエンス アンド バイオテクノロジー | 新規な抗ＥｐｈＡ２キメラ抗原受容体及びそれを発現する免疫細胞 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| WO1993000425A1 (en) | 1991-06-21 | 1993-01-07 | Amrad Corporation Limited | A novel receptor-type tyrosine kinase and use thereof |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| AU4116793A (en) | 1992-04-24 | 1993-11-29 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| NO175798C (no) | 1992-07-22 | 1994-12-07 | Sinvent As | Fremgangsmåte og anordning til aktiv stöydemping i et lokalt område |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| PT2180007E (pt) | 1998-04-20 | 2013-11-25 | Roche Glycart Ag | Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| DK2270147T4 (da) | 1999-04-09 | 2020-08-31 | Kyowa Kirin Co Ltd | Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle |
| ATE309385T1 (de) | 2000-06-28 | 2005-11-15 | Glycofi Inc | Verfahren für die herstellung modifizierter glykoproteine |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| WO2003078637A2 (en) | 2002-03-19 | 2003-09-25 | Plant Research International B.V. | Optimizing glycan processing in plants |
| CA2832136C (en) | 2002-09-27 | 2015-11-17 | Xencor | Optimized fc variants and methods for their generation |
| US7981843B2 (en) * | 2004-01-20 | 2011-07-19 | Kalobios Pharmaceuticals, Inc. | Antibody specificity transfer using minimal essential binding determinants |
| CA2577329A1 (en) | 2004-08-16 | 2006-03-02 | Medimmune, Inc. | Eph receptor fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity |
| US8222253B2 (en) * | 2004-10-23 | 2012-07-17 | Case Western Reserve University | Peptide and small molecule agonists of EphA and their uses |
| WO2006055778A2 (en) | 2004-11-16 | 2006-05-26 | Kalobios, Inc. | Immunoglobulin variable region cassette exchange |
| US8211648B2 (en) | 2005-07-22 | 2012-07-03 | Kalobios Pharmaceuticals, Inc. | Secretion of antibodies without signal peptides from bacteria |
| US7846724B2 (en) | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
| WO2008060092A1 (en) | 2006-11-17 | 2008-05-22 | Sang Yun Park | Rotative force generator |
| CA2679986C (en) | 2007-03-08 | 2018-03-06 | Martin Lackmann | Epha3 antibodies for the treatment of solid tumors |
| CL2008002782A1 (es) | 2007-09-21 | 2009-07-31 | Genentech Inc | Anticuerpo anti-bv8 neutralizante; composicion que lo comprende; y su uso para tratar tumores en humanos previamente tratados con un antagonista del factor de crecimiento endotelial vascular. |
| CN102405237A (zh) * | 2009-03-06 | 2012-04-04 | 卡罗拜奥斯制药公司 | 利用EphA3抗体治疗白血病和慢性骨髓增生性疾病 |
-
2010
- 2010-10-14 CN CN201080056618.XA patent/CN102666589B/zh active Active
- 2010-10-14 ES ES10777137T patent/ES2743558T3/es active Active
- 2010-10-14 DK DK10777137.0T patent/DK2488554T3/da active
- 2010-10-14 US US12/904,953 patent/US8664365B2/en active Active
- 2010-10-14 JP JP2012534368A patent/JP2013508292A/ja active Pending
- 2010-10-14 PT PT10777137T patent/PT2488554T/pt unknown
- 2010-10-14 AU AU2010313621A patent/AU2010313621C1/en active Active
- 2010-10-14 CA CA2777068A patent/CA2777068C/en active Active
- 2010-10-14 WO PCT/US2010/052725 patent/WO2011053465A1/en not_active Ceased
- 2010-10-14 EP EP10777137.0A patent/EP2488554B1/en active Active
- 2010-10-14 PL PL10777137T patent/PL2488554T3/pl unknown
-
2013
- 2013-12-30 US US14/143,427 patent/US9290571B2/en active Active
-
2015
- 2015-11-25 JP JP2015229465A patent/JP2016094424A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2743558T3 (es) | 2020-02-19 |
| CA2777068A1 (en) | 2011-05-05 |
| CA2777068C (en) | 2020-05-26 |
| WO2011053465A1 (en) | 2011-05-05 |
| PT2488554T (pt) | 2019-09-13 |
| JP2013508292A (ja) | 2013-03-07 |
| CN102666589A (zh) | 2012-09-12 |
| AU2010313621A1 (en) | 2012-05-03 |
| US20140120114A1 (en) | 2014-05-01 |
| DK2488554T3 (da) | 2019-09-02 |
| US20110123549A1 (en) | 2011-05-26 |
| AU2010313621C1 (en) | 2015-11-26 |
| AU2010313621B2 (en) | 2015-07-30 |
| EP2488554A1 (en) | 2012-08-22 |
| JP2016094424A (ja) | 2016-05-26 |
| US9290571B2 (en) | 2016-03-22 |
| EP2488554B1 (en) | 2019-07-24 |
| CN102666589B (zh) | 2014-08-20 |
| US8664365B2 (en) | 2014-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201107511B (en) | Antibodies specific to cadherin-17 | |
| SG10201701323TA (en) | Antibodies to ccr2 | |
| IL214996A0 (en) | Anti-bcma antibodies | |
| GB0920127D0 (en) | Antibodies | |
| GB0909906D0 (en) | Antibodies | |
| PT2488554T (pt) | Anticorpos para epha3 | |
| ZA201003876B (en) | Antibodies to gdf8 as uses thereof | |
| EP2125890A4 (en) | ANTIBODIES AGAINST PHOSPHORYLATED IRAQ4 | |
| SG10201401331TA (en) | Anti-siglec-15 antibody | |
| EP2427496A4 (en) | ANTI-VEGF-D ANTIBODIES | |
| ZA201105918B (en) | Fully human antibodies specific to cadm1 | |
| ZA201006658B (en) | Easy to open package | |
| GB0920324D0 (en) | Antibodies | |
| ZA201302983B (en) | Antibodies to notum pectinacetylesterase | |
| EP2499256A4 (en) | ANTI-C-MPL ANTIBODIES | |
| GB2473934B (en) | Anti-VEEV antibody | |
| GB0922448D0 (en) | Improvements to loudspeakers | |
| GB201013425D0 (en) | Improvement to packaging | |
| TWI365604B (en) | Delay circiuit | |
| GB0908945D0 (en) | Antibodies | |
| AU2009904982A0 (en) | Improved Alternative to Mulesing | |
| GB0801891D0 (en) | Brekkie to go range | |
| GB0805437D0 (en) | Aid to illustration enlargement | |
| GB0918637D0 (en) | Improvements relating to packaging | |
| GB0902094D0 (en) | Improvements to headphones |